PF-Atlas › Clinical Trials › NCT01519661

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

TBM100 · Phase 4

Registry ID

NCT01519661

Phase

Phase 4

Status

Completed

Drug / intervention

TBM100

Sponsor

Novartis Pharmaceuticals

Start

2012-01

Enrollment

157

Locations

About this trial

This study assessed the long term safety data for the use of tobramycin inhalation powder in patients suffering from cystic fibrosis who have a chronic pulmonary infection with Pseudomonas aeruginosa.

View NCT01519661 on ClinicalTrials.gov →

Explore related

All TBM100 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01519661 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.